Suppr超能文献

采用过继性 T 细胞疗法作为 HIV 治愈策略的一部分所面临的挑战与机遇。

Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy.

机构信息

Department of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

出版信息

J Infect Dis. 2021 Feb 15;223(12 Suppl 2):38-45. doi: 10.1093/infdis/jiaa223.

Abstract

HIV-infected individuals successfully controlling viral replication via antiretroviral therapy often have a compromised HIV-specific T-cell immune response due to the lack of CD4 T-cell help, viral escape, T-cell exhaustion, and reduction in numbers due to the withdrawal of cognate antigen. A successful HIV cure strategy will likely involve a durable and potent police force that can effectively recognize and eliminate remaining virus that may emerge decades after an individual undergoes an HIV cure regimen. T cells are ideally suited to serve in this role, but given the state of the HIV-specific T-cell response, it is unclear how to best restore HIV-specific T-cell activity prior initiation of a HIV cure strategy. Here, we review several strategies of generating HIV-specific T cells ex vivo that are currently being tested in the clinic and discuss how infused T cells can be part of an HIV cure strategy.

摘要

通过抗逆转录病毒疗法成功控制病毒复制的 HIV 感染者,由于缺乏 CD4 T 细胞辅助、病毒逃逸、T 细胞耗竭以及由于同源抗原的撤回导致数量减少,往往会导致 HIV 特异性 T 细胞免疫反应受损。成功的 HIV 治愈策略可能需要一个持久而有效的警察部队,该部队能够有效地识别和消除个体接受 HIV 治愈方案几十年后可能出现的剩余病毒。T 细胞是最适合担任这一角色的细胞,但鉴于 HIV 特异性 T 细胞反应的状态,目前尚不清楚在启动 HIV 治愈策略之前如何最好地恢复 HIV 特异性 T 细胞活性。在这里,我们回顾了几种目前正在临床中测试的体外生成 HIV 特异性 T 细胞的策略,并讨论了输注的 T 细胞如何成为 HIV 治愈策略的一部分。

相似文献

1
Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy.
J Infect Dis. 2021 Feb 15;223(12 Suppl 2):38-45. doi: 10.1093/infdis/jiaa223.
2
Fight fire with fire: Gene therapy strategies to cure HIV.
Expert Rev Anti Infect Ther. 2017 Aug;15(8):747-758. doi: 10.1080/14787210.2017.1353911. Epub 2017 Jul 14.
3
Advances in Developing CAR T-Cell Therapy for HIV Cure.
Front Immunol. 2020 Mar 10;11:361. doi: 10.3389/fimmu.2020.00361. eCollection 2020.
7
Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir.
Curr Opin Virol. 2019 Oct;38:21-30. doi: 10.1016/j.coviro.2019.04.004. Epub 2019 May 25.
8
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
Front Immunol. 2019 Sep 10;10:2109. doi: 10.3389/fimmu.2019.02109. eCollection 2019.
9
Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
EBioMedicine. 2019 May;43:295-306. doi: 10.1016/j.ebiom.2019.03.077. Epub 2019 Apr 2.

引用本文的文献

2
Cell therapies for viral diseases: a new frontier.
Semin Immunopathol. 2025 Jan 2;47(1):5. doi: 10.1007/s00281-024-01031-8.
3
Interventions during Early Infection: Opening a Window for an HIV Cure?
Viruses. 2024 Oct 9;16(10):1588. doi: 10.3390/v16101588.
5
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission.
Curr Opin HIV AIDS. 2024 Jul 1;19(4):169-178. doi: 10.1097/COH.0000000000000858. Epub 2024 May 1.
6
Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells.
PLoS Pathog. 2023 Dec 15;19(12):e1011853. doi: 10.1371/journal.ppat.1011853. eCollection 2023 Dec.
8
Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque.
Cell Rep Med. 2022 May 17;3(5):100614. doi: 10.1016/j.xcrm.2022.100614. Epub 2022 May 11.
9
The Search for an HIV Cure: Where Do We Go From Here?
J Infect Dis. 2021 Feb 15;223(12 Suppl 2):1-3. doi: 10.1093/infdis/jiaa738.

本文引用的文献

1
Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?
Cell Med. 2019 Jan 22;11:2155179018822781. doi: 10.1177/2155179018822781. eCollection 2019.
2
Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo.
Nature. 2020 Feb;578(7793):160-165. doi: 10.1038/s41586-020-1951-3. Epub 2020 Jan 22.
3
Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8 cells.
Nature. 2020 Feb;578(7793):154-159. doi: 10.1038/s41586-020-1946-0. Epub 2020 Jan 22.
4
Virus-specific T-cell therapies for patients with primary immune deficiency.
Blood. 2020 Feb 27;135(9):620-628. doi: 10.1182/blood.2019000924.
5
Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform.
Cell. 2019 Oct 31;179(4):880-894.e10. doi: 10.1016/j.cell.2019.10.002. Epub 2019 Oct 24.
6
CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.
Front Immunol. 2019 Sep 27;10:2310. doi: 10.3389/fimmu.2019.02310. eCollection 2019.
8
CAR T cells for infection, autoimmunity and allotransplantation.
Nat Rev Immunol. 2018 Oct;18(10):605-616. doi: 10.1038/s41577-018-0042-2.
9
10
Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor.
PLoS Pathog. 2017 Oct 12;13(10):e1006613. doi: 10.1371/journal.ppat.1006613. eCollection 2017 Oct.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验